Hutchison China MediTech Limited (HCM): Price and Financial Metrics
GET POWR RATINGS... FREE!
HCM POWR Grades
- Sentiment is the dimension where HCM ranks best; there it ranks ahead of 83.3% of US stocks.
- The strongest trend for HCM is in Quality, which has been heading up over the past 177 days.
- HCM's current lowest rank is in the Quality metric (where it is better than 22.93% of US stocks).
HCM Stock Summary
- The ratio of debt to operating expenses for HUTCHMED (CHINA) LTD is higher than it is for about only 4.28% of US stocks.
- With a year-over-year growth in debt of -98.83%, HUTCHMED (CHINA) LTD's debt growth rate surpasses just 1.09% of about US stocks.
- Revenue growth over the past 12 months for HUTCHMED (CHINA) LTD comes in at 75.81%, a number that bests 88.7% of the US stocks we're tracking.
- Stocks that are quantitatively similar to HCM, based on their financial statements, market capitalization, and price volatility, are NVEC, DBVT, VCNX, CANF, and GNFT.
- HCM's SEC filings can be seen here. And to visit HUTCHMED (CHINA) LTD's official web site, go to www.hutch-med.com.
HCM Valuation Summary
- HCM's price/sales ratio is 5.8; this is 16% higher than that of the median Healthcare stock.
- Over the past 82 months, HCM's price/earnings ratio has gone down 209.
Below are key valuation metrics over time for HCM.
HCM's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- HCM has a Quality Grade of D, ranking ahead of 20.42% of graded US stocks.
- HCM's asset turnover comes in at 0.31 -- ranking 145th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows HCM's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
HCM Stock Price Chart Interactive Chart >
HCM Price/Volume Stats
|Current price||$13.20||52-week high||$36.29|
|Prev. close||$13.71||52-week low||$7.39|
|Day high||$13.49||Avg. volume||527,914|
|50-day MA||$9.71||Dividend yield||N/A|
|200-day MA||$13.19||Market Cap||2.28B|
Hutchison China MediTech Limited (HCM) Company Bio
Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.
Most Popular Stories View All
HCM Latest News Stream
|Loading, please wait...|
HCM Latest Social Stream
View Full HCM Social Stream
Latest HCM News From Around the Web
Below are the latest news stories about HUTCHMED (CHINA) LTD that investors may wish to consider to help them evaluate HCM as an investment opportunity.
Company Executives Shared Vision and Answered Questions Live at VirtualInvestorConferences.comNEW YORK, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the presentations from its Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 16th and 17th are now available for online viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3GjK8UZThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials fr
In Tuesday’s session, HUTCHMED (China) Limited (NASDAQ:HCM) marked $11.54 per share, up from $10.98 in the previous session. While HUTCHMED (China) Limited has overperformed by 5.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HCM fell by -62.93%, with highs and lows ranging from $36.37 to […]
HUTCHMED (China) Limited (NASDAQ:HCM) marked $10.98 per share on Monday, up from a previous closing price of $9.90. While HUTCHMED (China) Limited has overperformed by 10.91%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HCM fell by -64.64%, with highs and lows ranging from $36.37 to […]
Hutchmed (China) (HCM) on Monday said that it will focus resources on its late-stage and registrational studies, while certain early-stage programs will not be prioritized for…
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today provides a corporate and strategic update, following an in-depth evaluation of the business. In response to the challenging market conditions currently affecting the global biopharmaceutical sector, HUTCHMED has taken a numb
HCM Price Returns
Continue Researching HCMWant to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:
Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch